Recurrent or metastatic nasopharyngeal carcinoma is an aggressive disease, and long-term survival with chemotherapy alone is ...

Photon therapy offers strong outcomes in treating oropharyngeal cancers; however, some radiation can reach and damage nearby ...

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

Erdafitinib showed a predictable toxicity profile and early efficacy in IDH–wild-type glioma with FGFR-TACC fusions. The recommended phase 2 dose was 8 mg daily, with one grade 3 central serous ...